Bruker Corporation (BRKR)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $9.41B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bruker Corporation (BRKR) Financials: Revenue, Profit and Cash Flow
Bruker reported revenue of $3.44B for the fiscal year ended Dec 31, 2025, up 2.1% from the year before. That year, net income was -$8.30M with a net margin of -0.2%, operating cash flow was $134.10M and free cash flow was $43.30M. The quarter ended Sep 30, 2026 had revenue of $874.00M and net income of -$109.70M.
Revenue and Margins
The operating margin was 2.0% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $1.61B, a compound annual rate of 8.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3.44B | +2.1% | 45.9% | 2.0% | -0.2% |
| Dec 2024 | $3.37B | +13.6% | 49.0% | 7.5% | 3.4% |
| Dec 2023 | $2.96B | +17.1% | 51.0% | 14.7% | 14.5% |
| Dec 2022 | $2.53B | +4.7% | 51.6% | 17.1% | 11.8% |
| Dec 2021 | $2.42B | +21.7% | 50.0% | 17.1% | 11.6% |
| Dec 2020 | $1.99B | -52.1% | 47.3% | 12.5% | 8.1% |
| Dec 2019 | $4.15B | +118.7% | 24.0% | 7.3% | 4.8% |
| Dec 2018 | $1.90B | +7.3% | 47.5% | 13.8% | 9.5% |
| Dec 2017 | $1.77B | +9.6% | 46.2% | 12.4% | 4.5% |
| Dec 2016 | $1.61B | N/A | 46.3% | 11.3% | 9.6% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.44B | $3.37B | $2.96B | $2.53B | $2.42B | $1.99B | $4.15B | $1.90B | $1.77B | $1.61B |
| Cost of revenue | $1.86B | $1.72B | $1.45B | $1.23B | $1.21B | $1.05B | $2.15B | $995.60M | $949.90M | $866.00M |
| Gross profit | $1.58B | $1.65B | $1.51B | $1.31B | $1.21B | $939.80M | $995.30M | $900.00M | $816.00M | $745.30M |
| Research and development | $395.20M | $376.50M | $294.80M | $235.90M | $220.80M | $198.00M | $187.70M | $173.40M | $161.60M | $147.90M |
| Operating income | $68.20M | $253.10M | $436.90M | $432.70M | $413.30M | $248.30M | $300.90M | $262.40M | $219.50M | $181.80M |
| Net income | -$8.30M | $113.80M | $428.50M | $298.50M | $280.60M | $161.40M | $198.00M | $181.00M | $80.30M | $154.50M |
| EBITDA | $242.30M | $390.70M | $659.10M | $502.70M | $482.70M | $306.20M | $356.00M | $309.60M | $261.70M | $231.90M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $874.00M | $838.50M | $823.40M | $977.20M | $860.50M | $797.40M | $801.40M | $979.60M | $864.40M | $800.70M | $721.70M | $854.50M |
| Gross profit | $429.30M | $416.00M | $379.80M | $449.20M | $379.40M | $357.90M | $391.20M | $493.30M | $418.80M | $384.60M | $352.80M | $430.30M |
| Operating income | -$91.00M | -$65.30M | $10.20M | $76.30M | -$51.80M | $11.90M | $31.80M | $72.10M | $68.10M | $48.10M | $64.80M | $103.50M |
| Net income | -$109.70M | -$50.90M | $15.70M | $29.20M | -$58.50M | $4.20M | $16.80M | $13.90M | $40.30M | $7.60M | $52.00M | $204.60M |
Balance Sheet
As of Dec 2025, total debt of $1.87B exceeded cash and equivalents by $1.57B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.24B | $5.81B | $4.25B | $3.61B | $3.65B | $3.05B | $2.77B | $2.13B | $1.95B | $1.81B |
| Current assets | $2.21B | $2.05B | $2.16B | $2.11B | $2.47B | $1.93B | $1.80B | $1.30B | $1.36B | $1.28B |
| Cash and equivalents | $298.80M | $183.40M | $488.30M | $645.50M | $1.07B | $681.80M | $678.30M | $322.40M | $325.00M | $342.40M |
| Total liabilities | $3.73B | $3.99B | $2.84B | $2.48B | $2.57B | $2.07B | $1.83B | $1.20B | $1.22B | $1.12B |
| Short-term debt | $16.60M | $32.50M | $121.20M | $18.70M | $112.40M | $2.20M | $500.00K | $18.50M | $415.60M | $20.10M |
| Long-term debt | $1.85B | $2.06B | $1.16B | $1.20B | $1.22B | $842.30M | $812.80M | $322.60M | $415.60M | $391.60M |
| Shareholder equity | $0 | $1.78B | $1.38B | $1.11B | $1.07B | $961.20M | $906.80M | $896.60M | $725.40M | $686.40M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $5.83B | $6.05B | $6.13B | $6.24B | $6.43B | $6.34B | $5.93B | $5.81B | $6.11B | $5.90B | $4.51B | $4.25B |
| Total liabilities | $3.49B | $3.62B | $3.63B | $3.73B | $3.94B | $4.47B | $4.08B | $3.99B | $4.27B | $4.08B | $3.06B | $2.84B |
| Cash and equivalents | $119.70M | $184.90M | $133.40M | $298.80M | $293.10M | $92.00M | $184.20M | $183.40M | $148.10M | $169.70M | $340.10M | $488.30M |
| Shareholder equity | $0 | $0 | $0 | $2.46B | $2.43B | $0 | $0 | $1.78B | $1.81B | $1.79B | $1.42B | $1.38B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 32.3% of operating cash flow. Dividends and share repurchases together came to 99.1% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $134.10M | $251.30M | $350.10M | $274.40M | $282.40M | $332.20M | $213.40M | $239.70M | $154.40M | $130.80M |
| Capital expenditures | $90.80M | $115.30M | $106.90M | $129.20M | $92.00M | $97.20M | $73.00M | $49.20M | $43.70M | $37.10M |
| Free cash flow | $43.30M | $136.00M | $243.20M | $145.20M | $190.40M | $235.00M | $140.40M | $190.50M | $110.70M | $93.70M |
| Dividends paid | $32.90M | $30.20M | $29.40M | $41.60M | $24.20M | $25.80M | $25.00M | $26.00M | $26.40M | $26.50M |
| Share repurchases | $10.00M | $0 | $152.30M | $263.10M | $153.30M | $123.20M | $142.30M | $0 | $152.20M | $160.00M |
| Investing cash flow | -$196.50M | -$1.76B | -$326.00M | -$251.60M | -$192.40M | -$192.70M | -$158.40M | -$123.40M | -$30.20M | -$21.80M |
| Financing cash flow | $135.10M | $1.23B | -$193.40M | -$415.30M | $318.70M | -$161.60M | $300.00M | -$112.40M | -$159.00M | -$27.90M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $118.20M | -$77.40M | $71.20M | $229.80M | -$33.20M | -$127.50M | $65.00M | $190.00M | $38.40M | $1.10M | $21.80M | $205.50M |
| Capital expenditures | $21.50M | $28.80M | $24.20M | $22.60M | $20.90M | $21.30M | $26.00M | $36.70M | $32.60M | $24.60M | $21.40M | $31.50M |
| Free cash flow | $96.70M | -$106.20M | $47.00M | $207.20M | -$54.10M | -$148.80M | $39.00M | $153.30M | $5.80M | -$23.50M | $400.00K | $174.00M |
Frequently Asked Questions About BRKR
What is Bruker's annual revenue?
Bruker reported revenue of $3.44B for the fiscal year ended Dec 31, 2025.
How fast is Bruker's revenue growing?
Revenue was up 2.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.7%.
Is Bruker profitable?
No. Bruker reported net income of -$8.30M for the fiscal year ended Dec 31, 2025, with a net margin of -0.2%.
How much free cash flow does BRKR generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $134.10M minus capital expenditures of $90.80M produced free cash flow of $43.30M.
How much debt does Bruker have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.85B, short-term debt of $16.60M and cash and equivalents of $298.80M.
BRKR pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts